Table of Contents

• Introduction to Dual SGLT1 and SGLT2 Inhibition
• Mechanism of Action: Renal and Intestinal Targets
• Landmark Clinical Trials: SOLOIST-WHF and SCORED
• Symptom Burden and Health Status Benefits
• Comparative Context and Meta-Analytic Evidence
• Adverse Effects and Clinical Monitoring
• Perioperative Management and Sick-Day Rules
• Frequently Asked Questions (FAQs)
• Medical Disclaimer
• References

Introduction to Dual SGLT1 and SGLT2 Inhibition

Heart failure remains a primary driver of cardiovascular morbidity and mortality, frequently coexisting with type 2 diabetes mellitus and chronic kidney disease. While selective sodium-glucose cotransporter 2 (SGLT2) inhibitors—such as dapagliflozin and empagliflozin—have become established pillars of guideline-directed medical therapy, sotagliflozin represents an expanded therapeutic approach through dual SGLT1 and SGLT2 inhibition. By inhibiting both transporters, sotagliflozin targets renal glucose reabsorption alongside gastrointestinal glucose and galactose absorption, producing distinct metabolic and hemodynamic effects.

Clinical evaluations have demonstrated the efficacy of sotagliflozin across the spectrum of left ventricular ejection fraction (LVEF), including heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), as well as in patients presenting with worsening heart failure decompensation. This educational review summarizes the mechanism of action, key clinical trial data, safety parameters, and practical management principles associated with sotagliflozin.

Mechanism of Action: Renal and Intestinal Targets

The physiological actions of sotagliflozin stem from its simultaneous inhibition of two distinct cotransporter proteins located in different organ systems:

• SGLT2 Inhibition (Renal Proximal Tubule): SGLT2 is high-capacity, low-affinity transporter primarily located in the early S1 segment of the renal proximal tubule, accounting for roughly 90% of filtered glucose reabsorption. Inhibiting SGLT2 promotes glycosuria and natriuresis, lowering plasma glucose while reducing intravascular volume, systemic blood pressure, and intraglomerular hypertension.
• SGLT1 Inhibition (Gastrointestinal Tract and Distal Tubule): SGLT1 is a high-affinity, low-capacity transporter predominantly expressed in the apical membrane of enterocytes within the small intestine, as well as the S3 segment of the renal proximal tubule. By delaying intestinal glucose and galactose absorption, sotagliflozin blunts postprandial glucose excursions and prolongs distal gut transit, which stimulates the endogenous secretion of glucagon-like peptide-1 (GLP-1). In the kidney, residual glucose reabsorption in the S3 segment is also attenuated.

Landmark Clinical Trials: SOLOIST-WHF and SCORED

The clinical efficacy of sotagliflozin was established in two large randomized, double-blind, placebo-controlled Phase 3 clinical trials: SOLOIST-WHF and SCORED.

The SOLOIST-WHF Trial: Worsening Heart Failure

The SOLOIST-WHF trial evaluated 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure, randomized to either sotagliflozin or placebo [1]. Therapy was initiated either prior to hospital discharge (48.8%) or within a median of two days following discharge (51.2%).

Over a median follow-up of 9.0 months, sotagliflozin demonstrated a significant 33% relative risk reduction in the primary composite endpoint of cardiovascular death, hospitalizations for heart failure, and urgent heart failure visits (51.0 vs. 76.3 events per 100 patient-years; hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001) [1]. Efficacy was evident early after initiation and remained consistent regardless of whether treatment was commenced inpatient or immediately post-discharge, highlighting the feasibility of early therapeutic optimization.

The SCORED Trial: Diabetes and Chronic Kidney Disease

The SCORED trial enrolled 10,584 patients with type 2 diabetes, chronic kidney disease (estimated glomerular filtration rate [eGFR] of 25 to 60 mL/min/1.73 m²), and elevated cardiovascular risk, followed for a median of 16 months [2].

Sotagliflozin significantly reduced the primary composite outcome of cardiovascular deaths, heart failure hospitalizations, and urgent visits compared with placebo (5.6 vs. 7.5 events per 100 patient-years; HR, 0.74; 95% CI, 0.63 to 0.88; P<0.001) [2]. In addition, an analysis of the original coprimary endpoint—first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke—demonstrated a favorable reduction (HR, 0.84; 95% CI, 0.72 to 0.99) [2].

Symptom Burden and Health Status Benefits

Beyond reducing hospitalizations, disease-modifying therapies must address patient functional capacity and symptom burden. A prespecified analysis of the SOLOIST-WHF trial assessed patient-reported health status utilizing the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) [3].

Patients treated with sotagliflozin experienced significant, clinically meaningful improvements in overall KCCQ-12 summary scores by month 4 compared to placebo (adjusted mean difference, 4.1 points; 95% CI, 1.3 to 7.0; P=0.005) [3]. A higher proportion of patients receiving sotagliflozin achieved at least a 5-point improvement (odds ratio, 1.38; 95% CI, 1.06 to 1.80), demonstrating tangible relief from physical limitations and heart failure symptoms across ejection fraction categories [3].

Comparative Context and Meta-Analytic Evidence

In network meta-analyses evaluating SGLT class therapies in patients with heart failure and diabetes, sotagliflozin consistently reduced composite cardiovascular death and heart failure hospitalizations alongside selective agents such as empagliflozin and dapagliflozin [4]. Broader meta-analyses of SGLT inhibitors confirm renal protective benefits in both diabetic and non-diabetic chronic kidney disease populations, attenuating progression toward end-stage renal disease [5].

Adverse Effects and Clinical Monitoring

While sotagliflozin is generally well-tolerated, its combined intestinal and renal actions create a specific profile of potential adverse effects that clinicians must anticipate.

Gastrointestinal Events

Due to intestinal SGLT1 inhibition and the resulting osmotic load of unabsorbed carbohydrates in the bowel lumen, gastrointestinal disturbances—specifically diarrhea—occur more frequently with sotagliflozin than with placebo (6.1% vs. 3.4% in SOLOIST-WHF; and elevated in SCORED) [1], [2]. Symptoms are typically mild to moderate and diminish over time, but patient counseling regarding hydration is essential.

Genital Mycotic Infections and UTIs

As with selective SGLT2 inhibitors, sustained glycosuria promotes fungal overgrowth. Genital mycotic infections (such as vulvovaginal candidiasis and candida balanitis) were significantly more frequent in trial cohorts receiving sotagliflozin [2]. Routine hygiene education and prompt antifungal therapy manage most cases.

Diabetic Ketoacidosis (DKA)

An increased risk of diabetic ketoacidosis—frequently presenting with normal or only modestly elevated blood glucose levels (euglycemic DKA)—is a recognized class effect of SGLT inhibitors that was observed in both SCORED and broader class meta-analyses [2], [5]. Patients and clinicians must maintain a high index of suspicion for non-specific symptoms such as malaise, nausea, vomiting, tachypnea, and abdominal pain.

Volume Depletion and Hypotension

Through osmotic diuresis and natriuresis, sotagliflozin can produce intravascular volume contraction. Clinicians should evaluate volume status prior to initiation, particularly in elderly patients or individuals receiving intensive background loop diuretic therapy. Baseline eGFR should also be evaluated before initiating therapy.

Perioperative Management and Sick-Day Rules

To minimize the risk of precipitated ketoacidosis during physiologic stress:

• Perioperative Holds: SGLT inhibitors should generally be temporarily withheld at least three days prior to major elective surgeries or procedures requiring prolonged fasting.
• Acute Medical Illness: The medication should be suspended during severe acute illnesses, critical infections, persistent vomiting, or dehydration until oral intake and metabolic stability are restored.

Frequently Asked Questions (FAQs)

How does sotagliflozin differ from dapagliflozin or empagliflozin?

Dapagliflozin and empagliflozin selectively target renal SGLT2. In contrast, sotagliflozin is a dual inhibitor targeting both SGLT2 in the kidney and SGLT1 in the gastrointestinal tract and distal nephron. This dual mechanism contributes to reduced postprandial glucose absorption in the gut alongside urinary glucose excretion, though it is associated with a modestly higher incidence of diarrhea.

When was sotagliflozin studied for initiation after acute heart failure?

In the SOLOIST-WHF trial, sotagliflozin was initiated either immediately prior to discharge or within days after discharge in patients stabilized following decompensated heart failure, demonstrating early reductions in cardiovascular events within 30 days of initiation.

Can sotagliflozin cause low blood sugar (hypoglycemia)?

When used as monotherapy, the risk of hypoglycemia with SGLT inhibitors is low because their mechanism does not directly stimulate insulin secretion. However, when co-administered with sulfonylureas or exogenous insulin, the risk of severe hypoglycemia is increased, and downward adjustment of concomitant insulin secretagogues or insulin may be necessary.

Medical Disclaimer

This article is provided for educational and informational purposes only and does not constitute formal medical advice, clinical diagnosis, or individualized treatment recommendations. Clinical decisions regarding sotagliflozin or other cardiovascular pharmacotherapies should be made in consultation with an appropriately qualified physician or healthcare provider. Patients experiencing symptoms suggestive of ketoacidosis, severe dehydration, or worsening heart failure should seek immediate medical evaluation. This draft remains subject to independent physician review prior to publication.

References

• Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B, SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-128. View on PubMed
• Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG, SCORED Investigators. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129-140. View on PubMed
• Bhatt AS, Bhatt DL, Steg PG, Szarek M, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Testani JM, Wilcox CS, Davies M, Pitt B, Kosiborod MN. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF. J Am Coll Cardiol. 2024;84(16):1501-1512. View on PubMed
• Kongmalai T, Hadnorntun P, Leelahavarong P, Kongmalai P, Srinonprasert V, Chirakarnjanakorn S, Chaikledkaew U, McKay G, Attia J, Thakkinstian A. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1287408. View on PubMed
• Qian J, Xu Y. Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: An updated drug/dose-dependent meta-analysis. Clin Nephrol. 2026;105(3):145-156. View on PubMed